Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P‐Glycoprotein Activities. Issue 6 (28th March 2022)

• Record Type: Journal Article
• Authors: Achour, Brahim; Gosselin, Pauline; Terrier, Jean; Gloor, Yvonne; Al‐Majdoub, Zubida M.; Polasek, Thomas M.; Daali, Youssef; Rostami‐Hodjegan, Amin; Reny, Jean‐Luc
• Is Part Of: Clinical pharmacology & therapeutics. Volume 111:Issue 6(2022)
• Page Start: 1268
• Page End: 1277
• Publication Date: 2022-03-28
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2576
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Precision dosing strategies require accounting for between‐patient variability in pharmacokinetics together with subsequent pharmacodynamic differences. Liquid biopsy is a valuable new approach to diagnose disease prior to the appearance of clinical signs and symptoms, potentially circumventing invasive tissue biopsies. However, the possibility of quantitative grading of biomarkers, as opposed to simply confirming their presence or absence, is relatively new. In this study, we aimed to verify expression measurements of cytochrome P450 (CYP) enzymes and the transporter P‐glycoprotein (P‐gp) in liquid biopsy against genotype and activity phenotype (assessed by the Geneva cocktail approach) in 30 acutely ill patients with cardiovascular disease in a hospital setting. After accounting for exosomal shedding, expression in liquid biopsy correlated with activity phenotype for CYP1A2, CYP2B6, CYP2C9, CYP3A, and P‐gp ( r = 0.44–0.70, P ≤ 0.05). Although genotype offered a degree of stratification, large variability (coefficient of variation (CV)) in activity (up to 157%) and expression in liquid biopsy (up to 117%) was observed within each genotype, indicating a mismatch between genotype and phenotype. Further, exosome screening revealed expression of 497 targets relevant to drug metabolism and disposition (159 enzymes and 336 transporters), as well as 20 molecular drug targets. Although there were no functional data available to correlate against these large‐scale measurements, assessment of disease perturbation from healthy baseline was possible. Verification of liquid biopsy against activity phenotype is important to further individualize modeling approaches that aspire to achieve precision dosing from the start of drug treatment without the need for multiple rounds of dose optimization.